Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of M9466 with irinotecan-based regimens in advanced solid tumors and colorectal cancer
jRCT2031240418Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of M9466, irinotecan, folinic acid, fluorouracil and bevacizumab in Nonhematologic neoplasms and colorectal cancer (CRC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Number of participants with treatment-emergent adverse events and treatment-related treatment-emergent adverse events and Number of participants with dose-limiting toxicity. Started Nov 2024; status: completed.
02
Drugs
M9466irinotecanfolinic acidfluorouracilbevacizumab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031240418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240418.